Engflag

Decolgen P

Quick links to important sections

Decolgen P

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Decolgen P

Property Description
Active Ingredients Chlorpheniramine, Paracetamol, Phenylephrine
Form Oral Preparation (Tablet)
Pharmacological Class Antihistamine, Analgesic/Antipyretic, Decongestant
General Purpose Symptomatic relief of cold and flu manifestations
Type Fixed-Dose Combination (FDC)

What Type of Medicine is Decolgen P?

Decolgen P is a synthetic, Fixed-Dose Combination (FDC) product, typically administered as an oral preparation in tablet form, designed for the simultaneous management of multiple discomforts. It is classified as a multi-symptom cold and flu preparation, generally positioned as an Over-The-Counter (OTC) solution. This FDC structure simplifies the process of providing coordinated relief, as the preparation integrates three distinct active ingredients into a singular entity. This approach is clinically recognized for offering convenience in the initial stages of cold and flu, helping individuals address common discomforts swiftly.

Decolgen P Composition: A Triple-Action Profile

The specific nature of Decolgen P is defined by its three core active ingredients, each belonging to a unique pharmacological class. These components are Chlorpheniramine, an antihistamine that works against allergic responses; Paracetamol (Acetaminophen), a non-opioid analgesic and antipyretic for pain and fever; and Phenylephrine, a sympathomimetic decongestant. Paracetamol is an established and widely accepted agent for the primary management of fever and mild-to-moderate pain. The integration of these three distinct classes provides a broad spectrum of action that covers the most prevalent manifestations associated with common cold and allergic rhinitis.

The General Purpose of This Combination Preparation

The overall purpose of this integrated composition is to achieve systemic and concurrent symptomatic relief in a single dose. This combination is commonly used in scenarios like the onset of influenza-like symptoms, where an individual experiences fever, muscle aches, and significant nasal congestion simultaneously. The structure is intended to simplify the management of these common, co-occurring discomforts, allowing for coordinated relief from the symptoms that collectively define the condition.

Regulatory References

  1. World Health Organization (WHO) Essential Medicines List
  2. WHO Analgesic Ladder

What side effects are possible with Decolgen P?

Possible side effects and safety information

The official safety profile for this fixed-dose combination, containing Chlorpheniramine, Paracetamol, and Phenylephrine, is based on documented adverse reactions and regulatory constraints for its components.

Officially Classified Adverse Reactions

Adverse reactions are classified by frequency and associated System-Organ Classes (SOC) in regulatory documents, including the Nervous System, Gastrointestinal, Cardiac, and Hepatobiliary systems.

Frequency Classification Key Adverse Reactions (Officially Listed)
Very Common Sedation, Somnolence (Drowsiness)
Common Dizziness, Dry Mouth, Nausea, Disturbance in Attention
Not Known Severe Hepatic Injury, Blood Dyscrasias, Severe Skin Reactions

Sedation and somnolence, the most Very Common effects, typically manifest at the start of treatment.

Serious Adverse Reactions and Safety Constraints

The label explicitly documents the potential for serious adverse reactions, including Severe Hepatic Injury or failure (associated with the Paracetamol component) and Severe Cutaneous Adverse Reactions (e.g., SJS, TEN).

Population-specific safety notes advise caution for certain groups:

  • Older Adults are more susceptible to anticholinergic effects like confusion and urinary retention.
  • Individuals with Severe Hepatic Impairment or pre-existing conditions like severe hypertension or narrow-angle glaucoma have regulatory limitations on use.

Safety documents also strictly prohibit combining this product with other Paracetamol-containing medicines to prevent exceeding the maximum safe daily dose.

Overdose and Emergency Response

The official regulatory documents state that an overdose of this combination product is a serious medical emergency due to the toxicological profiles of its components. Immediate medical attention must be sought if an overdose is suspected, even if symptoms are not present. This requirement is due to the potential for delayed, severe toxicity, particularly from the Paracetamol component.

Overdose manifestations are documented across multiple physiological systems. The Paracetamol component carries the risk of severe hepatic necrosis (liver damage) and acute kidney injury, outcomes that may necessitate liver transplantation. Initial symptoms can be non-specific, including nausea, vomiting, sweating, extreme tiredness, or upper abdominal tenderness.

The Chlorpheniramine component may result in severe Central Nervous System (CNS) effects, such as agitation, confusion, hallucinations, seizures, or respiratory depression. Concurrently, the Phenylephrine component may induce cardiovascular risks, including hypertensive crisis, severe bradycardia, or potentially life-threatening cardiac arrhythmias.

Regulators mandate that emergency services or Poison Control must be contacted immediately for suspected overdose. For Paracetamol toxicity, the specific antidote, N-acetylcysteine (NAC), is approved and must be administered urgently. Management requires hospital monitoring, including continuous cardiac surveillance and frequent laboratory checks to assess organ function.

Therapeutic Uses of Decolgen P

This fixed-dose combination is commonly used to provide supportive symptomatic relief for manifestations of the Common Cold, Influenza-like symptoms, and Allergic Rhinitis. It is relevant in contexts where symptoms may interfere with daily functioning and plays a role in managing the overall symptom load during acute episodes.

It is applied in clinical settings that involve acute or unstable symptom patterns, supporting the management of symptoms related to physical discomfort, systemic imbalance, and inflammatory or irritative states.

Therapeutic Scope and Benefit

This preparation is commonly used to help with symptoms such as fever, generalized body aches, headache, nasal congestion (stuffy nose), rhinorrhea (runny nose), and sneezing. When these symptoms cluster into patterns that interfere with daily comfort, the combination supports patients by offering coordinated symptomatic relief.

“This approach is relevant when supportive symptom management is appropriate for multiple, concurrent acute manifestations.”

Quick Fact: Relief for Co-occurring Symptoms

The preparation helps manage these symptoms simultaneously, which contributes to improved day-to-day comfort and helps patients cope more steadily during symptomatic periods where manifestations are noticeable.

Regulatory References

  1. NIH DailyMed overview of this combination

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Decolgen P

Official regulatory documentation for this Paracetamol, Chlorpheniramine, and Phenylephrine combination establishes clear constraints for its use.

Population Status Regulatory Rule (Official Labeling)
Allowed Adults and adolescents ge 12 years (standard tablet formulations).
Not Recommended Pregnant women and breastfeeding mothers. Children under 4 years of age.
Contraindicated Patients with known hypersensitivity to any component; those taking MAO Inhibitors (or within 14 days of cessation); severe hypertension or severe cardiovascular disease; narrow-angle glaucoma; or severe hepatic or renal impairment.
Restriction Category Conditional/Cautionary Use (SmPC/FDA)
Chronic Conditions Use with caution in patients with diabetes mellitus, hyperthyroidism, epilepsy, or prostatic hypertrophy.
Organ Function Use with caution in patients with mild to moderate renal or hepatic dysfunction.

Eligibility is defined by mandatory exclusion criteria (Contraindications) and explicit population restrictions (e.g., age and reproductive status), which dictate who must not use the medicine and who requires restricted use. Use is only permitted for non-contraindicated individuals who meet the approved age threshold.

What should I know about interactions with other medicines?

Decolgen P is a combination product whose official regulatory interaction profile is defined by its three components: Chlorpheniramine, Paracetamol, and Phenylephrine. The profile establishes formal regulatory prohibitions and conditions for co-administration with other medicines and substances.

Formal Contraindications and Timing Rules

Co-administration is contraindicated with several substance classes. This product must not be taken with Monoamine Oxidase Inhibitors (MAOIs), a prohibition that extends for fourteen days after stopping MAOI therapy. It is also restricted from co-use with other Sympathomimetic Amines due to additive cardiovascular risk, and with other Paracetamol-containing products to avoid overdose.

Documented Pharmacodynamic and Exposure Interactions

Pharmacodynamic interactions lead to potentiation of effects. Co-administration with Central Nervous System (CNS) Depressants may increase sedative effects. The Phenylephrine component may reduce the effectiveness of certain Antihypertensives and increase the risk of cardiovascular events, including when combined with Tricyclic Antidepressants or Cardiac Glycosides.

Pharmacokinetic interactions can alter exposure. Metoclopramide or Domperidone may officially increase the speed of Paracetamol absorption, while Colestyramine may reduce it. The Chlorpheniramine component is documented to inhibit the metabolism of Phenytoin, potentially resulting in toxicity. Regarding other substances, Alcohol may potentiate both sedation and hepatotoxicity. The enhanced anticoagulant effect of Warfarin is officially associated only with the prolonged regular daily use of the Paracetamol component, not occasional use.

Mechanism of Action

The mechanism of action is based on the concurrent operation of three distinct pharmacological components, targeting biological processes that modulate thermoregulation, vascular tone, and histamine-driven reflexes.

Modulating Central Thermoregulation and Pain Signaling

This domain involves the action of Paracetamol, which primarily inhibits the synthesis of Prostaglandin E2 ( PGE2) within the Central Nervous System (CNS). By reducing the influence of PGE2 on the hypothalamic thermostat, the drug facilitates the adjustment of the set point, allowing for peripheral heat dissipation mechanisms to operate. This component also engages descending pathways in the CNS to modulate nociceptive (pain) signals, contributing to a reduction in pain signal transmission.

Regulating Nasal Vascular Tone via alpha1 Receptors

The Phenylephrine component operates by acting as an Agonist at the Alpha-1 (alpha1) Adrenergic Receptors on the blood vessels of the nasal mucosa. Activating these receptors initiates a cellular cascade that causes the local vascular smooth muscle to contract, resulting in the physical reduction of tissue volume and edema. This mechanism contributes to a reduction in the impact of engorged blood vessels on airway resistance.

Blocking Histamine and Secretory Pathways

The mechanism of Chlorpheniramine is defined by its role as a Competitive Antagonist at the Histamine H1 Receptors, blocking the action of histamine released by the body. This blockade helps limit the effects of histamine on capillary permeability and glandular secretion, and modulates histamine-driven reflexes.

Dosage and Administration Information

The administration of Decolgen P, a Fixed-Dose Combination (FDC) oral tablet, is governed by official instructions detailing the proper route, dosing schedule, maximum daily constraint, and duration of use. The medicine is strictly for oral administration.

Official Administration Guidelines

Feature Official Instruction
Route of Administration Oral administration only.
Dosing Schedule Adults and children 12 years and older: 1 to 2 tablets per dose.
Frequency and Timing Doses are taken every 4 to 6 hours as needed for symptom management.
Preparation / Ingestion The tablet must be swallowed whole with water; it must not be crushed, chewed, or dissolved.
Maximum Daily Constraint A strict daily limit must be observed, generally not exceeding 6 to 8 tablets within any 24-hour period.
Course Duration The product is intended for short-term use, with official instructions typically advising against continuous administration for more than 7 days.
Age-Group Rules The preparation is not for use in children under 4 years of age. Dosing for children 4 to 12 years requires consultation with a health professional.

Procedural Structure

The required protocol involves swallowing the unit dose whole and maintaining the precise interval between administrations to manage total drug exposure. If a dose is missed when the medicine is taken on a regular schedule, the official guidance is to skip the missed dose if the next is due soon and never to double the unit amount. These instructions define the standardized, regulated approach to using the medicine.

Recent Clinical Evidence

Evidence for Symptomatic Relief of Cold and Flu-Like Illness

Research was applied to study conditions characterized by fluctuating or episodic manifestations, such as the common cold or flu-like illness. The combination of Chlorpheniramine, Paracetamol, and Phenylephrine was evaluated in research exploring these contexts, focusing on outcomes related to physical discomfort and systemic imbalance. The evidence base includes short-term randomized controlled trials (RCTs) that included a placebo comparison. Findings describe patterns observed in the studies, with some trials reporting measurements of changes across composite symptom scales. This research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Scope of Studies and Measured Outcomes

The primary research method used to evaluate this combination involves comparative trials. Research also examined the component drugs, focusing on outcomes linked to physiological strain, fever, and irritative states. Outcomes reflecting daily functioning or activity level, such as the time to reported return to normal activities, were studied for. Most controlled research was evaluated in adults aged 18 to 60 years old. While post-marketing studies have explored the combination in other groups, comparative evidence is lacking for very young populations, such as children and infants. Follow-up durations were limited, with detailed assessments typically occurring over a period of 48 to 72 hours. Long-term effects are not fully established.

Key Limitations and Uncertainties

A key area of uncertainty relates to the specific components. Official regulatory reviews have noted that current scientific data on the orally administered Phenylephrine component (the decongestant) do not align with the standard expectation for effectiveness for nasal decongestion at the common oral doses studied. Additionally, evidence quality varies across studies, and sample sizes were modest in some cases. Evidence highlights what is known—and what is still uncertain—about this combination.

Key Studies & References

  1. ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE tablet (NIH DailyMed Monograph)
  2. WHO Model List of Essential Medicines - 23rd List (2023) (supporting Paracetamol's established use)

How should Decolgen P be stored and disposed of?

How to Store and Dispose of Decolgen P?

The official storage profile for Decolgen P (Paracetamol, Chlorpheniramine, Phenylephrine) is strictly defined by regulatory requirements to ensure stability and safety.

Official Storage Requirements

  • Temperature: Store at a controlled room temperature, typically 20 C to 25 C. Avoid excessive heat above 40 C and do not freeze.
  • Protection: The product must be stored protected from light and excessive moisture (humidity). Do not store in the bathroom.
  • Packaging: Keep the medication in the original, tightly closed container and verify that the package or blister unit is not tampered with.
  • Child Safety: The medication MUST be kept out of the sight and reach of children at all times.

Official Disposal Rules

Disposal: Unused or expired medication should not be flushed down the toilet or poured into a drain unless explicitly authorized. Follow local regulatory guidelines for pharmaceutical disposal. No special requirements apply for hazardous waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Decolgen P found in:

A-Z Index: